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Introduction
Cancers of the upper aerodigestive tract, collectively 
known as head and neck cancers, arise from a myriad of 
sites, including the oral cavity, pharynx, and larynx, as 
well as the nasal cavity and sinuses [1–3]. Oropharyngeal 
cancer (OPC) is a rare cancer overall but common in the 
head and neck region [4]. Head and neck cancer is the sixth 
most common type of cancer, making up 5.3% of all cases 
and account for an estimated 348,300 new cancer cases 
and 179,600 cancer deaths worldwide per year [5]. The 
median age for diagnosis is around mid-60s, with male 
predominance, especially for laryngeal cancer [6]. Squa-
mous cell carcinomas (SCC) of varying degrees of differ-
entiation make up the majority of head and neck cancers 
[2, 3]. About two-thirds of these SCC patients present at an 
advanced stage, usually with nodal involvement [3].
There is wide discrepancy in treating head and neck can-
cer. In recent decades, there has been a tendency towards 
organ preserving treatment [2] and as most head and neck 
cancers respond well to radiotherapy (at least in the first 
instance), surgery can be avoided in a high proportion of 
cases [2]. Chemotherapy has accentuated this organ pre-
serving approach [2]. National Comprehensive Cancer 
Network (NCCN) guidelines consider concurrent chemo-
radiation therapy (CCRT) as first-line treatment for oro-
pharyngeal cancers; however, the evidence supporting this 
is equivocal [7].
All treatment modalities have their pros and cons. Sur-
gery may result in loss of function associated with exci-
sion of anatomical structures, whereas radiotherapy may 
be accompanied by debilitating dysphagia and long-term 
loss of oral lubrication [2]. Radiotherapy induces fibrosis 
in the muscles of mastication, leading to trismus, as well 
as necrosis of bone and soft tissue which restricts mouth 
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opening [8, 9]. Chemotherapy too is associated with signifi-
cant morbidity and can cause renal dysfunction, ototoxicity, 
and myelosuppression [2]. Decisions on treatment modality 
depend on the tumour site and stage, expected functional 
outcomes and the patients comorbidities and ability to tol-
erate treatment [3]. There is currently no consensus as to 
which treatment modality results in better outcomes.
Trismus, which is restricted mouth opening, is common 
in head and neck cancer patients and interferes with activi-
ties, such as eating, swallowing, and speaking [10, 11]. It 
also interferes with oral hygiene and can be particularly 
discomforting to patients [12]. Trismus may be caused by 
tumour infiltration into the masticatory muscles, specifi-
cally the pterygoids, or temporomandibular joint (TMJ) 
or induced by cancer treatment, including surgery and/or 
radiotherapy(RT) [13, 14]. Post-treatment trismus is unpre-
dictable in both its frequency and severity [12] and usually 
develops 3–6 month post-radiotherapy and often becomes a 
lifelong problem [13].
Prevention of trismus is more desirable than treating it 
[14]. Patients at risk of trismus should have home exercises 
to maintain maximum mouth opening and jaw mobility 
as soon as they start radiotherapy [15, 16]. Patients who 
develop trismus require an intensive exercise programme, 
and if necessary, combined with physiotherapy to improve 
mouth opening [15]. Prosthetic appliances (dynamic bite 
openers) containing springs and bands are able to re-stretch 
the muscles to help patients suffering from trismus [15, 
16]. Patient concordance with trismus exercises is para-
mount if preventative and treatment regimes are to be suc-
cessful [17].
Review aim
Trismus can be measured both objectively and subjectively. 
The goal of this review is to compare the different tools for 
the subjective measures of trismus and assess the most suit-
able questionnaire to be used for measuring trismus. We 
include a systematic literature review to compare the effect 
of different head and neck cancer treatment modalities on 
trismus using subjective measures encountered.
Objective measures of trismus
Normal mouth opening varies between individuals, within 
a range of 40–60 mm [18]. Males generally display greater 
mouth opening than females [19]. Maximal interincisal 
opening (MIO) is the maximal distance between the edges 
of the upper and lower incisors and is widely used to objec-
tively measure trismus [8, 10, 11, 20–23]. For edentulous 
patients, the distance from one alveolar ridge to the oppos-
ing side vertically can be used instead [14]. These meas-
urements can be made using callipers or other devices 
[11, 20]. The MIO should be measured before treatment 
is commenced, and the patient or clinician should measure 
this distance frequently post-treatment to ensure its mainte-
nance [17]. As there is no agreed absolute measurement of 
trismus in clinical practice, studies have mostly used a cut-
off of ≤35 mm [10, 11, 21–26].
Subjective measure of trismus
Patients may continue to experience trismus in spite of 
objectively ‘normal’ MIO. The emergence of the patient 
reported outcome measures (PROMs) and quality-of-life 
questionnaires allows clinicians to look beyond mortality as 
the sole outcome measure of successful medical interven-
tions. Subjective measures can also be used to compare dif-
ferent treatments [27]. Such subjective measures of trismus 
are vital in managing this condition.
Our review identified several questionnaires that address 
trismus (Table 1). These subjective trismus measures con-
sist of either a mouth opening specific questionnaires, such 
as the Mandibular Function Impairment Questionnaire 
(MFIQ) [21], or a subset question in a general cancer qual-
ity-of-life questionnaire, such as the Performance Status 
Scale (PSS) [28].
Table 1  Summary of questionnaires
Mouth-opening specific questionnaires General quality-of-life questionnaires
Mandibular Function Impairment Questionnaire (MFIQ) [21] European Organization for Research and Treatment of Cancer (EORTC) 
QLQ-C30 questionnaire [7, 8, 23, 24, 27, 29–32]
The Liverpool Oral Rehabilitation Questionnaire (LORQ v3) [26, 33] EORTC QLQ-H&N35 questionnaire [7, 8, 23, 24, 27, 29–32]
Gothenburg Trismus Questionnaire (GTQ) [20] Performance Status Scale (PSS) [28]
The University of Washington quality-of-life scale (UWQOL v4) [23, 
26]
Functional Assessment of Cancer Therapy—Head and Neck Scale 
(FACT-H&N) [34]
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There is a suggested definition of severe trismus with 
a PSS score of ≤50, European Organization for Research 
and Treatment of Cancer (EORTC) QLQ-C30 and EORTC 
QLQ-H&N35 ≥50 [28].
Mouth‑opening specific questionnaires
The first study that aimed to determine the cutoff for tris-
mus used the Mandibular Function Impairment Question-
naire (MFIQ) [21]. This questionnaire contains 11 items 
which assessed perceived difficulties in mandibular func-
tion during social activities, speaking, taking large bites, 
chewing hard food, chewing soft food, work and/or daily 
activities, drinking, laughing, chewing resistant food, 
yawning, and kissing [21]. There were also six other items 
which took into account difficulties during eating specific 
foods, i.e., a hard cookie, meat, a raw carrot, French bread, 
peanuts/almond, and an apple [21]. Answers were scored 
(0) no difficulty, (1) a little difficulty, (2) quite a bit of dif-
ficulty, (3) much difficulty, and (4) very great difficulty or 
impossible without help [21]. Scores were summed up, 
with a range between 0 and 68 and a high score indicat-
ing more impairment [21]. The internal consistency of the 
questionnaire lies between 0.80 and 0.95 [29].
The Liverpool Oral Rehabilitation Questionnaire 
(LORQ v3) comprises 40 items, whereby 17 relate to oral 
function, oro-facial appearance, and social interaction 
[30]. Five questions were included to assess the impact of 
chewing ability on social life and choice of food: (1) did 
you experience difficulty with chewing? (2) did you have 
pain when you chew? (3) did your chewing ability affect 
your social life? (4) did your chewing ability influence 
your choice of foods? and (5) did you experience difficulty 
with mouth opening? [26] Options for an answer included 
‘Always’, ‘Often’, ‘Sometimes’, or ‘Never’ [26].
The Gothenburg Trismus Questionnaire (GTQ) is a tris-
mus specific questionnaire with good psychometric prop-
erties (validity and reliability), but has only been used in 
one study [20]. This questionnaire contains 21 items with 
13 items divided into the three domains: jaw-related prob-
lems (six items); eating limitations (four items); and mus-
cular tension (three items) [20]. The domains and single 
items range from 0 to 100; 100 indicating maximal amount 
of symptoms and 0 being symptom free [20]. The GTQ 
has a 1 week recall period for the three domains [20]. 
Patients with trismus reported more health-related qual-
ity-of-life impairments in the domains of mouth opening 
(p < 0.001), jaw-related problems (p < 0.05), eating limi-
tations (p < 0.05), and muscular tension (p < 0.001) [20]. 
These results were in line with the incidence of trismus, 
and are compatible with results from other studies [8, 20, 
31]. The GTQ has been suggested as a screening tool and 
for evaluating endpoints in intervention for jaw physiother-
apy and rehabilitation studies [20].
General quality‑of‑life questionnaires
The PSS consists of three subscales, such as eating in pub-
lic, normalcy of diet, and intelligibility of patients speech 
[28, 32]. Each is rated from 0 to 100, whereby higher 
scores suggest better performance [32].
The UWQOL v4 is validated in the field of head and 
neck cancers but is not as widely used as the EORTC ques-
tionnaires [26]. It assesses 12 domains: pain, appearance, 
activity, recreation, swallowing, chewing, speech, shoul-
der function, taste, saliva, mood, and anxiety, whereby the 
chewing, saliva, mood, and anxiety domains which are 
measured on a Likert scale from 0 (worst) to 100 (best) 
were included in the study questionnaire to identify the 
effects of limited mouth opening on these domains [26]. 
There was no mention of a scoring system to define trismus 
using the UWQOL [26].
The FACT uses means of self-reporting and comprises 
28 general + 11 head and neck specific items, rated from 
0 to 4 on a Likert-type scale [32]. The FACT domains 
describe function in six areas: physical well-being, social 
and family well-being, relationship with doctor, emotional 
well-being, functional well-being, and head- and neck-
related symptoms (HNS) [32, 33]. The FACT-H&N mod-
ule includes additional concerns, such as oral comfort, 
breathing, voice, eating, appearance, tobacco, alcohol, and 
communication [33].
The EORTC developed an established system assess-
ing the health related quality of life (QOL) of head and 
neck cancer patients using two questionnaires, the general 
EORTC QLQ-C30 questionnaire, and the head- and neck-
specific EORTC QLQ-H&N35 module which subjectively 
measured mouth opening among the six scales [34]. The 
EORTC QLQ-C-30 is a self-assessment of health-related 
QOL for patients with cancer, including difference function 
scores, a score for global QOL, and symptoms scores rel-
evant for cancer patients [28, 35]. The five functional scales 
are physical, role, emotional, cognitive, and social func-
tioning, while the six symptom scores include dyspnoea, 
insomnia, appetite loss, constipation, diarrhoea, and finan-
cial difficulties [28]. The supplementary EORTC QLQ-
H&N35 consists of 35 additional questions to assess head 
and neck cancer-related symptoms (7 multi-item scales and 
11 single items, validated in a sample of 500 patients from 
Norway, Sweden, and The Netherlands) [28, 35, 36]. Scales 
and single questions are scored on categorical scales and 
linearly converted to a scale of 0-100 [35]. A score of 100 
on the functioning scales and the Global QOL scale rep-
resents maximal functioning, while a score of 100 on the 
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symptom scales and single items indicate worst possible 
symptoms [20]. Changes in the score of >10 points over 
time could be clinically significant [20]. The multi-item 
scales consist of pain, swallowing, senses, speech, social 
eating, social contact, and sexuality, while the single items 
are teeth, mouth opening, dry mouth, sticky saliva, cough-
ing, feeling ill, pain killers, nutritional supplements, feed-
ing tube, weight loss, and weight gain [28]. High function 
scores and a low symptom scores correlate to good func-
tioning and few symptoms [35]. The EORTC has been used 
worldwide, including a validated Chinese version of the 
EORTC core questionnaire and head and neck module [37]. 
These questionnaires have been continuously re-evaluated 
and proven to be sensitive and comprehensive [38, 39].
Correlation between subjective and objective 
trismus measures
A couple of studies used both objective and subjec-
tive measurements for trismus [20, 23, 26]. Correlation 
between objective measurements of mouth opening and 
subjective measures using the UWQOL questionnaire 
has been attempted. This identified a significant associa-
tion of mouth opening on the UWQOL chewing domain 
(rs  =  0.45, p < 0.0001) and in the UWQOL overall qual-
ity of life (rs  =  0.25, p = 0.01) [26]. However, there were 
exceptions whereby 16 patients with objective trismus 
denied problems with mouth opening while ten patients 
who were not shown clinically to have trismus complained 
subjectively of problems with mouth opening [26]. Despite 
this, correlation between subjective and objective measure-
ments was overall strong.
Other studies that used subjective or objective measures 
have had comparable finding. Studies using objective meas-
ures found that patients who received adjuvant radiotherapy 
and multi-modality treatments had worst outcomes than 
those treated with surgery alone, in line with studies meas-
uring trismus subjectively [8, 22, 25, 26, 40, 41]. The dif-
ference in mean MFIQ scores for patients with trismus and 
without trismus for a cut-off point of ≤35 mm was signifi-
cant [21]. An MFIQ score of 8.3 was the minimum score of 
for trismus, equivalent to a mouth opening of 35 mm [21].
Materials and methods
Search strategy
The preferred reporting items for systematic review and 
meta-analyses (PRISMA) guidelines were used to perform 
a systematic review of available literature. Studies evaluat-
ing the effects of different types of head and neck cancers, 
especially the oropharyngeal region on mouth opening, 
were searched for using PubMed, Cochrane Library, Sci-
ence Direct, Scopus, EMBASE (1947–Present) and Ovid 
MEDLINE (1946 to May Week 2 2015). Four search 
domains were used and combined using “AND”, while 
terms within each domain combined by “AND/OR”. The 
keywords “head and neck cancer”, “SCC oropharynx”, 
“oropharyngeal cancer”, “oropharyngeal carcinoma”, 
“SCC base of tongue”, “tonsil SCC”, “oropharyngeal neo-
plasm”, “oropharyngeal tumor”, “oropharyngeal tumour”, 
and “cancer of the oropharynx” were used in the first 
domain. The second domain encompassed “mouth open-
ing”, “jaw opening”, and “trismus”. Finally, the terms 
“surgery”, “radiotherapy”, “radiation therapy”, “chemo-
therapy”, “chemoradiotherapy”, “chemoradiation”, “chem-
otherapy and radiotherapy”, “chemotherapy and radiation 
therapy”, and “transoral robotic surgery” were used in the 
third domain. The final domain consisted of “quality of 
life”.
The primary search identified 3243 records. 3146 of 
these were excluded following screening. 59 of the remain-
ing studies were duplicates, thus leaving 38 studies for full 
text evaluation. Eight studies were added through cross-ref-
erencing. Following application of our inclusion and exclu-
sion criteria to these full texts, a further 11 studies were 
excluded. A total of 35 studies were included, 19 involv-
ing subjective measures of trismus, while the other 16 only 
measured trismus objectively. Six subjective studies, which 
compared treatment modalities, were chosen for the final 
review (Fig. 1).
Inclusion and exclusion criteria
Original journal articles that studied the effects of oro-
pharyngeal carcinoma treatment on mouth opening as 
assessed using qualitative measurements were included. 
Eligible, studies needed to be carried out on humans, 
involve ten or more patients, included post-treatment 
measurements, and included treatment with surgery, radi-
otherapy (RT), chemotherapy, or a combination of any of 
the three modalities. Articles were excluded if there was 
no patient involvement, unrelated to head and neck oncol-
ogy, written in languages other than English, and focused 
on dental hygiene during oncology treatment or primarily 
discussed exercise regimes to treat trismus. Letters to the 
editor, case reports/series (<10 participants) and poster 
abstracts were also excluded.
Results
The questionnaires used in the studies included in the sys-
tematic review were the EORTC QLQ-C30 and EORTC 
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QLQ-H&N35 [7, 27, 42–45]. None of these studies used 
objective measures to measure trismus. Table  2 shows a 
summary of the studies that were included in this review.
Ryzek et  al. showed significantly better results among 
early stage oropharyngeal cancer (OPC) for the surgery-
only treatment group when compared to either surgery 
combined with RT or surgery combined with any type 
of adjuvant therapy for mouth opening (p ≤ 0.05) in the 
EORTC-QLQ-HN35 [27].
A further study evaluating OPC patients using the 
EORTC QLQ-H&N35 questionnaire [43] found that radia-
tion therapy significantly augmented the patient’s com-
plaint about restricted mouth opening (surgery versus 
radiation, p = 0.008; surgery versus surgery plus irradiation, 
p = 0.0008) [43]. When patients undergoing surgery ± RT 
were compared with the non-surgically treated group 
(radiation therapy alone), patients in the no surgery group 
suffered significantly more from restricted mouth opening 
Fig. 1  Trismus search strategy 
to obtain literature using 
PRISMA guidelines
Records identified through database searching (n=3263) 
PubMed (n=534), Cochrane Library (n=9), Science Direct (n=1473), Scopus (n=759), 
EMBASE (n=366), Ovid MEDLINE (n=122) 
Full-text articles assessed for eligibility (n=97) 
Excluded as did not meet inclusion criteria 
(n=3166) 
Full-text articles (n=38) 
Exclusion of duplicate study reports (n=59) 
Full-text articles (n=46) 
Additional relevant articles (n=8) 
Full-text articles (n=35) 
Exclusion after review by supervisor due to no 
measure (n=11) 
Subjective (n=19) Objective (n=16) 
Subjective (n=6) 
Exclusion after applying inclusion and exclusion 
criteria (n=13) 
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(p = 0.03) [43]. Comparison between patients receiving any 
kind of radiation therapy ± surgery and those treated with 
surgery alone, radiation therapy leads to significantly more 
problems with mouth opening (p = 0.001) [43].
Kim et  al. investigated OPC cancer patients and found 
that there was no significant difference in mouth opening 
between the surgery-based group and the RT-based group 
(p = 0.9024) [7].
Boscolo-Rizzo et  al. analysed OPC patients and found 
that the chemoradiotherapy (CRT) group reported signifi-
cantly greater problems with mouth opening (p = 0.036, 
mean difference 18.1) when compared with those who had 
surgery + postoperative RT [44].
Postoperative radiotherapy had a significant correlation 
to impact mouth opening on the EORTC QLQ-H&N35 
symptom scale among patients who had undergone mar-
ginal or segmental mandibular resection for oral and oro-
pharyngeal squamous cell carcinoma (OSCC) (p = 0.003, 
p ≤ 0.003) [42].
Patients who had recently been diagnosed with squa-
mous cell oral and oropharyngeal carcinoma, who under-
went surgery combined with adjuvant RT and chemother-
apy presented worse evaluations of QoL, more affectation 
of less oral opening compared to those who had surgery 
alone [45].
Discussion
Subjective quality-of-life measures are a concurrent part 
of modern surgical practice. Ideally, these questionnaires 
should be validated [27]. Other QOL questionnaires, such 
as the mandibular function impairment questionnaire 
(MFIQ) [21] and Performance Status Scale (PSS) [28], 
have not been validated, while Van Der Molen et al. used a 
study-specific questionnaire for QOL evaluation [46].
The European Organization for Research and Treatment 
of Cancer have shown a great interest in module develop-
ment. A module may assess (1) the disease symptoms 
related to a specific tumour site (e.g., abdominal pain in 
colorectal cancer), (2) the side-effects relating to a specific 
treatment (e.g., radiotherapy-induced skin problems), or (3) 
additional QoL domains affected by the disease of treat-
ment (e.g., sexuality, body image and future perspective) 
[47]. The developmental process of these questionnaires is 
subjected to internal peer review to ensure uniformly high-
quality modules. These sets of questionnaires have under-
gone three phases of module development, psychometric 
performance, and cross-cultural validity [47]. The multi-
national, cross-cultural, and multidisciplinary composition 
of the EORTC study group have enabled crucial scientific 
and cultural input to the development of the modules [47]. 
These are among the reasons that the EORTC QLQ sets 
of questionnaires have been extensively used in studies 
to measure trismus in head and neck cancer. The LORQ 
questionnaire has showed promising abilities to assess 
oral rehabilitation in patients with oral and oropharyngeal 
cancer, showing good construct validity and reliability in 
a pilot study [48]. It was used alongside the UWQOL and 
the EORTC QLQ questionnaires to determine its validity 
and reliability [48]. However, the study size was small and 
future studies might have to look into analysing this ques-
tionnaire with a larger cohort [48].
Although the EORTC QLQ-C30 and the QLQ-H&N35 
have been used more frequently, it is undeniable that the 
GTQ questionnaire is a potential successor as it was found 
to be useful in identifying patients’ change in functional 
mouth opening over time [20]. As for now, the EORTC 
QLQ sets of questionnaires are the set standard for a thor-
ough, valid, and reliable method to determining quality of 
life in head and neck cancer patients.
Surgery
Nonsurgical treatments, deemed less invasive, are assumed 
to lead to better QoL outcomes [44, 49]. However, Ryzek 
et  al. using the EORTC questionnaire for mouth opening 
reported higher scores among surgery-only patients when 
compared to surgery plus RT or any adjuvant therapy [27].
Patients undergoing surgery ± RT had less restricted 
mouth opening, using subjective measures, than the non-
surgically treated patients. In this group, primary surgical 
resection achieved the highest QoL score in the head and 
neck specific EORTC QLQ-H&N35 module of the three 
treatment modalities [43]. However, careful interpretation 
is required as these patients presented with a lower initial 
tumour stage than those treated with primary radiother-
apy or surgery plus adjuvant radiotherapy [43]. We have 
included Trans Oral Robotic Surgery (TORS) in our search, 
but it did not yield any trismus related PROMs or studies.
Radiotherapy
The EORTC QLQ-C30 and H&N35 used to subjectively 
measure trismus revealed that non-irradiated patients 
had significantly less trouble with mouth opening com-
pared to those treated with either primary or postopera-
tive radiation therapy [43]. However, mouth opening was 
not significantly different between surgery-based and 
RT-based treatment in a study by Kim et  al. who also 
used the EORTC QLQ-C30 and H&N35 [7, 43].
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Chemotherapy
Positive predictive factors of trismus include treatment 
with concurrent chemoradiotherapy [50]. The CRT treat-
ment group reported significantly greater problems with 
trismus than surgical patients using EORTC QLQ-C30 & 
QLQ-HV35 [44], where patients with T3-4 oropharyngeal 
cancer after surgery plus postoperative RT (26 patients) 
were compared to versus CCRT (31 patients). Conflicting 
results, using the subjective measures do arise, as seen by 
Payakachat et  al. when using the EORTC QLQ-H&N35, 
the median score differences on the open mouth item were 
significantly higher in the Surgery + RT group when com-
pared with the CRT group [51].
Multimodality treatment
Few studies compare QOL outcomes in different treatment 
modalities of oropharyngeal cancers [52, 53]. The studies 
that do look at QOL outcomes do not specifically look into 
the aspect of mouth opening [52, 53]. Only Infante-Cossio 
et  al. showed that patients who underwent surgical treat-
ment combined with adjuvant radiotherapy and chemo-
therapy generally showed a worse score for mouth opening, 
needing a longer recovery time compared to surgery alone 
and surgery plus RT [45].
Tumour staging
One study showed that patients in stages III and IV had a 
worse evaluation of their state of health and QoL, showing 
a higher incidence of pain, tiredness, less appetite, more 
swallowing problems, speech problems and problems with 
social contacts and eating in public, limited oral opening 
cough, weight loss, and more analgesia consumption [45]. 
There is a significant association between tumour staging 
and QoL problems [41, 54–56]. Patients with early stage 
cancer showed better overall QoL, both at the beginning 
and after 1 year, than those at more advanced stages [45].
Trismus study design
As per guidelines, mouth opening should be measured 
throughout treatment. For the purposes of future research, 
we have devised an algorithm for future studies to demon-
strate when to measure for trismus at the various stages of 
the patients’ treatment and follow-up (Fig.  2). This algo-
rithm includes minimum points for trismus assessment and 
data capture, i.e., at the time of diagnosis, post treatment, 
and after rehabilitation. We suggest using the EORTC set 
of questionnaires, which are the EORTC QLQ-C30 and 
the EORTC QLQ-H&N35 as they were the most estab-
lished and were used in the studies included in our sys-
tematic review. We suggest a further trismus assessment 
1 year post-treatment as studies report no further changes 
in health-related quality of life after the first postoperative 
year [57]. We suggest that patients should be followed up 
for at least 3 years [45].
Limitations
Our systematic review of subjective outcome measures 
contained studies with small cohorts. Furthermore, the 
existence of numerous confounding factors when com-
paring different treatment modalities, which cannot be 
eliminated are an ongoing limitation while utilising sub-
jective trismus measures [27]. Other limitations include 
lack of information on the relationship between objective 
and subjective measures in most studies, hence not being 
able to ascertain the reliability of other questionnaires in 
Fig. 2  Algorithm for measur-
ing trismus in future studies. 
Assessment to include the fol-
lowing: Objective use callipers 
or similar instrument to measure 
the inter-incisor distance. Docu-
ment in patient notes and/or 
database. Subjective use ques-
tionnaire (EORTC QLQ-C-30 
and EORTC QLQ-H&N35) to 
score patients’ reported percep-
tion of trismus. Questionnaire 
added to patients’ notes and/or 
database
Pre-Treatment 
Assessment
During Treatment 
Assessment 
For patients at medium or 
high risk of trismus
Follow-up Assessment 
(at 1-3 years)
To monitor effectiveness of 
interventions
Post-Treatment 
Assessment (at 6 months)
Early Intervention
Mouth opening exercises 
Jaw rehabilitation devices
Intervention
Mouth opening exercises 
Jaw rehabilitation devices 
Trismus 
identified
Risk Stratification 
Based on treatment 
location and disease 
Trismus 
identified
No 
Trismus
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practice. There are also variations between questionnaires 
in how they determine QoL with regard to the type of 
questions asked and also indirect parameters that suggest 
or can cause difficulty in mouth opening, such as chew-
ing, speech, and pain. Some studies also focused on cer-
tain types of cancer, such as oropharyngeal cancer, while 
others took into account generally all cancers of the head 
and neck.
Conclusion
Subjective measures were utilised to measure post-oper-
ative trismus successfully. While cure rates are given the 
greatest priority and treatment if guided by the UICC 
grade, subjective measures, such as patient, reported 
outcome measures (PROMs) and QoL questionnaires 
are important and useful tools for assessing patient well-
being. This is particularly important in head and neck 
cancer, where the treatment modalities result in equal 
effectiveness.
These subjective measures, QoLs and PROMs, are 
also of use in monitoring side effects of treatment, e.g., 
trismus, so that early intervention can be implemented 
to treat or prevent progression. This manuscript demon-
strates that future head and neck cancer treatment stud-
ies must incorporate functional measurements together 
with QOL measurements, because functional improve-
ments alone do not correlate to a perceived improvement 
in trismus outcomes according to patients [7]. We envis-
age future studies prospectively performing objective and 
subjective measures of mouth opening prior, during and 
after treatment. Subjective measures may be early indi-
cators of developing trismus, which would have implica-
tions for early intervention.
Compliance with ethical standards 
Funding The authors did not receive any financial support or other 
external help in preparing this manuscript.
Conflict of interest The authors declare that they have no conflict 
of interest.
Ethical approval This article does not contain any studies with 
human participants or animals performed by any of the authors.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References 
 1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) 
Head and neck cancer. N Engl J Med 3:184–194
 2. Tobias JS (1994) Cancer of the head and neck. BMJ 
308:961–966
 3. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head 
and neck cancer. Lancet (London, England) 371:1695–1709
 4. Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre 
J-L (2002) Cancer of the oropharynx. Crit Rev Oncol Hematol 
41:107–122
 5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D 
(2011) Global cancer statistics. CA Cancer J Clin 61:69–90
 6. SEER Cancer Statistics Review, 1975–2013. http://seer.cancer.
gov/csr/1975_2013/. Accessed 23 Oct 2016
 7. Kim TW, Youm HY, Byun H, Son YI, Baek CH (2010) Treat-
ment outcomes and quality of life in oropharyngeal cancer after 
surgery-based versus radiation-based treatment. Clin Exp Otorhi-
nolaryngol 3:153–160
 8. Weber C, Dommerich S, Pau HW, Kramp B (2010) Limited 
mouth opening after primary therapy of head and neck cancer. 
Oral Maxillofac Surg 14:169–173
 9. Wang C-J, Huang E-Y, Hsu H-C, Chen H-C, Fang F-M, Hsiung 
C-Y (2005) The degree and time-course assessment of radiation-
induced trismus occurring after radiotherapy for nasopharyngeal 
cancer. Laryngoscope 115:1458–1460
 10. Jager-Wittenaar H, Dijkstra PU, Vissink A, van Oort RP, Rood-
enburg JLN (2009) Variation in repeated mouth-opening meas-
urements in head and neck cancer patients with and without tris-
mus. Int J Oral Maxillofac Surg 38:26–30
 11. Lee L-Y, Chen S-C, Chen W-C, Huang B-S, Lin C-Y (2015) 
Postradiation trismus and its impact on quality of life in patients 
with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral 
Radiol 119:187–195
 12. Vissink a, Jansma J, Spijkervet FKL, Burlage FR, Coppes RP 
(2003) Oral sequelae of head and neck radiotherapy. Crit Rev 
Oral Biol Med 14:199–212
 13. Ichimura K, Tanaka T (1993) Trismus in patients with malignant 
tumours in the head and neck. J Laryngol Otol 107:1017–1020
 14. Goldstein M, Maxymiw WG, Cummings BJ, Wood RE (1999) 
The effects of antitumor irradiation on mandibular opening and 
mobility: a prospective study of 58 patients. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod 88:365–373
 15. Dreizen SA, Dally TE, Drane JB, Brown LR (1977b) Oral com-
plications of cancer radiotherapy. Postgr Med 61:85–92
 16. Engelmeier RL, King GE (1983) Complications of head and 
neck radiation therapy and their management. J Prosthet Dent 
49:514–522
 17. Vissink A, Burlage FR, Spijkervet FKL, Jansma J, Coppes RP 
(2003) Prevention and treatment of the consequences of head 
and neck radiotherapy. Crit Rev Oral Biol Med 14:213–225
 18. Dhanrajani PJ, Jonaidel O (2002) Trismus: aetiology, differential 
diagnosis and treatment. Dent Update 29:88–92, 94.
 19. Dworkin SF, Huggins KH, LeResche L, Von Korff M, Howard 
J, Truelove E, Sommers E (1990) Epidemiology of signs and 
symptoms in temporomandibular disorders: clinical signs in 
cases and controls. J Am Dent Assoc 120:273–281
 20. Pauli N, Johnson J, Finizia C, Andréll P (2013) The incidence of 
trismus and long-term impact on health-related quality of life in 
patients with head and neck cancer. Acta Oncol 52:1137–1145
 21. Dijkstra PU, Huisman PM, Roodenburg JLN (2006) Criteria for 
trismus in head and neck oncology. Int J Oral Maxillofac Surg 
35:337–342
 22. Kamstra JI, Dijkstra PU, van Leeuwen M, Roodenburg JLN, 
Langendijk JA (2015) Mouth opening in patients irradiated for 
2706 Eur Arch Otorhinolaryngol (2017) 274:2695–2707
1 3
head and neck cancer: a prospective repeated measures study. 
Oral Oncol 51:548–555
 23. Lee R, Slevin N, Musgrove B, Swindell R, Molassiotis A (2012) 
Prediction of post-treatment trismus in head and neck cancer 
patients. Br J Oral Maxillofac Surg 50:328–332
 24. Van Der Molen L, Heemsbergen WD, De Jong R, Van Rossum 
MA, Smeele LE, Rasch CRN, Hilgers FJM (2013) Dysphagia 
after chemoradiotherapy Dysphagia and trismus after concomi-
tant chemo-Intensity-Modulated Radiation Therapy (chemo-
IMRT) in advanced head and neck cancer; Dose-effect relation-
ships for swallowing and mastication structures. Radiother Oncol 
106:364–369
 25. Scott B, D’Souza J, Perinparajah N, Lowe D, Rogers SN (2011) 
Longitudinal evaluation of restricted mouth opening (trismus) in 
patients following primary surgery for oral and oropharyngeal 
squamous cell carcinoma. Br J Oral Maxillofac Surg 49:106–111
 26. Scott B, Butterworth C, Lowe D, Rogers SN (2008) Factors 
associated with restricted mouth opening and its relationship to 
health-related quality of life in patients attending a Maxillofacial 
Oncology clinic. Oral Oncol 44:430–438
 27. Ryzek D-F, Mantsopoulos K, Künzel J, Grundtner P, Zenk J, 
Iro H, Psychogios G (2014) Early stage oropharyngeal carcino-
mas: comparing quality of life for different treatment modalities. 
Biomed Res Int 2014:421964
 28. Teguh DN, Levendag PC, Voet P, van der Est H, Noever I, de 
Kruijf W, van Rooij P, Schmitz PIM, Heijmen BJ (2008) Trismus 
in patients with oropharyngeal cancer: relationship with dose in 
structures of mastication apparatus. Head Neck 30:622–630
 29. Stegenga B, L. G. M. de Bont, de Leeuw GB R (1993) Assess-
ment of mandibular function impairment associated with tempo-
romandibular joing osteoarthrosis and internal derangement. J 
Orofac Pain 7:183–195
 30. Pace-Balzan A, Cawood JI, Howell R, Butterworth CJ, Lowe D, 
Rogers SN (2006) The further development and validation of the 
Liverpool Oral Rehabilitation Questionnaire: a cross-sectional 
survey of patients attending for oral rehabilitation and general 
dental practice. Int J Oral Maxillofac Surg 35:72–78
 31. Hutcheson, Katherine A, Lewin JS (2012) Functional outcomes 
after chemoradiotherapy of laryngeal and pharyngeal cancers. 
Curr Oncol Rep 14:158–165
 32. List MA, D’Antonio LL, Cella DF, Siston A, Mumby P, Haraf 
D, Vokes E (1996) The performance status scale for head and 
neck cancer patients and the functional assessment of cancer 
therapy-head and neck scale: a study of utility and validity. Can-
cer 77:2294–2301
 33. Duke RL, Campbell BH, Indresano AT, Eaton DJ, Marbella 
AM, Myers KB, Layde PM (2005) Dental status and quality of 
life in long-term head and neck cancer survivors. Laryngoscope 
115:678–683
 34. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, 
Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM 
d., Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, 
Sneeuw K, Sullivan M, Takeda F (1993) The European Organi-
zation for Research and Treatment of Cancer QLQ-C30: a qual-
ity-of-life instrument for use in international clinical trials in 
oncology. JNCI J Natl Cancer Inst 85:365–376
 35. Huguenin PU, Taussky D, Moe K, Meister A, Baumert B, Lütolf 
UM, Glanzmann C (1999) Quality of life in patients cured from a 
carcinoma of the head and neck by radiotherapy: The importance 
of the target volume. Int J Radiat Oncol Biol Phys 45:47–52
 36. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boy-
sen M, Evensen JF, Biörklund A, de Leeuw JR, Fayers PM, Jan-
nert M, Westin T, Kaasa S (1999) Quality of life in head and 
neck cancer patients: validation of the European Organization 
for Research and Treatment of Cancer Quality of Life Question-
naire-H&N35. J Clin Oncol 17:1008–1019
 37. Ng W-MR, Wei IW (2006) Quality of life of patients with recur-
rent nasopharyngeal carcinoma treated with nasopharyngectomy 
using the maxillary swing approach. Arch Otolaryngol Head 
Neck Surg 132:309–316
 38. Bjordal K, Kaasa S (1992) Psychometric validation of the 
EORTC Core Quality of Life Questionnaire, 30-item version and 
a diagnosis-specific module for head and neck cancer patients. 
Acta Oncol 31:311–321
 39. Bjordal K, AhlnerElmqvist M, Tollesson E, Jensen AB, Razavi 
D, Maher EJ, Kaasa S: Development of A European-Organiza-
tion-For-Research-And-Treatment-Of-Cancer (Eortc) question-
naire module to be used in quality-of-life assessments in head 
and neck-cancer patients. Acta Oncologica 1994:879–885
 40. Steiner F, Evans J, Marsh R, Rigby P, James S, Sutherland K, 
Wickens R, Nedev N, Kelly B, Tan ST (2015) Mouth opening 
and trismus in patients undergoing curative treatment for head 
and neck cancer. Int J Oral Maxillofac Surg 44:292–296
 41. Rogers SN, Lowe D, Patel M, Brown JS, Vaughan ED (2002) 
Clinical function after primary surgery for oral and oropharyn-
geal cancer: an 11-item examination. Br J Oral Maxillofac Surg 
40:1–10
 42. Van Cann EM, Dom M, Koole R, Merkx MAW, Stoelinga PJW 
(2005) Health related quality of life after mandibular resection 
for oral and oropharyngeal squamous cell carcinoma. Oral Oncol 
41:687–693
 43. Tschudi D, Stoeckli S, Schmid S (2003) Quality of life after dif-
ferent treatment modalities for carcinoma of the oropharynx. 
Laryngoscope 113:1949–1954
 44. Boscolo-Rizzo P, Stellin M, Fuson R, Marchiori C, Gava A, Da 
Mosto MC (2009) Long-term quality of life after treatment for 
locally advanced oropharyngeal carcinoma: surgery and post-
operative radiotherapy versus concurrent chemoradiation. Oral 
Oncol 45:953–957
 45. Infante-Cossio P, Torres-Carranza E, Cayuela A, Hens-Aumente 
E, Pastor-Gaitan P, Gutierrez-Perez JL (2009) Impact of treat-
ment on quality of life for oral and oropharyngeal carcinoma. Int 
J Oral Maxillofac Surg 38:1052–1058
 46. Van Der Molen L, Van Rossum MA, Burkhead LM, Smeele LE, 
Rasch CRN, Hilgers FJM (2011) A randomized preventive reha-
bilitation trial in advanced head and neck cancer patients treated 
with chemoradiotherapy: feasibility, compliance, and short-term 
effects. Dysphagia 26:155–170
 47. Sprangers MAG, Cull A, Groenvold M, Bjordal K, Blazeby J, 
Aaronson NK (1998) The European Organization for Research 
and Treatment of Cancer approach to developing questionnaire 
modules: an update and overview. Qual Life Res 7:291–300
 48. Pace-Balzan A, Cawood JI, Howell R, Lowe D, Rogers SN 
(2004) The liverpool oral rehabilitation questionnaire: a pilot 
study. J Oral Rehabil 31:609–617
 49. Tribius S, Bergelt C: Intensity-modulated radiotherapy versus 
conventional and 3D conformal radiotherapy in patients with 
head and neck cancer: Is there a worthwhile quality of life gain?. 
Cancer Treat Rev 2011:511–519
 50. Jeremic G, Venkatesan V, Hallock A, Scott D, Hammond A, 
Read N, Franklin J, Yoo J, Fung K (2011) Trismus following 
treatment of head and neck cancer. J Otolaryngol Head Neck 
Surg 40:323–329
 51. Payakachat N, Ounpraseuth S, Suen JY (2013) Late complica-
tions and long-term quality of life for survivors (> 5 years) with 
history of head and neck cancer. Head Neck 35:819–825
 52. Broglie M a., Soltermann A, Haile SR, Röösli C, Huber GF, 
Schmid S, Stoeckli SJ (2013) Quality of life of oropharyngeal 
cancer patients with respect to treatment strategy and p16-posi-
tivity. Laryngoscope 123:164–170
 53. Tschiesner U, Schuster L, Strieth S, Harréus U (2012) Func-
tional outcome in patients with advanced head and neck cancer: 
2707Eur Arch Otorhinolaryngol (2017) 274:2695–2707 
1 3
surgery and reconstruction with free flaps versus primary radio-
chemotherapy. Eur Arch Otorhinolaryngol 269:629–638
 54. Graeff A d., JR d. L, WJ R, GJ H, GH B, JA W (1999) A pro-
spective study on quality of life of patients with cancer of the 
oral cavity or oropharynx treated with surgery with or without 
radiotherapy. Oral Oncol 35:27–32
 55. de Graeff a, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, 
Winnubst J a (2000) Long-term quality of life of patients with 
head and neck cancer. Laryngoscope 110:98–106
 56. Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Boysen M, Even-
sen JF, Biorklund A, Jannert M, Kaasa S, Sullivan M, Westin T 
(2001) A prospective study of quality of life in head and neck 
cancer patients. Part I: at diagnosis. Laryngoscope 111(4 Pt 
1):669–680
 57. Rogers SN, Hannah L, Lowe D, Magennis P (1999) Quality of 
life 5–10 years after primary surgery for oral and oro-pharyngeal 
cancer. J Craniomaxillofac Surg 27:187–191
